CFO Matthew Gall (TNGX) files Form 3 with no reported trades

Rhea-AI Filing Summary

Tango Therapeutics, Inc. filed an initial Form 3 for Chief Financial Officer Matthew Gall. The filing identifies him as an officer but, in the provided data, shows no reportable transactions, derivative positions, or other holdings, indicating this is a baseline ownership statement rather than a trading disclosure.

Key Terms

Form 3, Chief Financial Officer, reporting person

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Financial Officer financial

""officer_title": "Chief Financial Officer""

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

reporting person regulatory

""reportingPersons": [ { "name": "Gall Matthew""

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gall Matthew

(Last) (First) (Middle)

C/O TANGO THERAPEUTICS, INC.

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/15/2026

3. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24: Power of Attorney

No securities are beneficially owned.

	/s/ Julie Fogarty, as attorney-in-fact	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Tango Therapeutics (TNGX) Form 3 for Matthew Gall show?

The Form 3 lists Matthew Gall as Chief Financial Officer and reporting person for Tango Therapeutics. In the provided data, it shows no reportable transactions, holdings, or derivative positions, serving as an initial baseline ownership filing.

Are there any stock purchases or sales in the TNGX Form 3 for Matthew Gall?

No stock purchases or sales appear in this Form 3 excerpt. The transaction summary indicates zero buy, sell, acquire, or dispose events, suggesting the filing is purely an initial ownership report without trading activity disclosed here.

Does Tango Therapeutics CFO Matthew Gall report derivative securities on this Form 3?

No derivative securities are reported in this Form 3 excerpt. The derivativeSummary is empty and the transactionSummary shows zero derivative transactions, indicating no options or similar instruments are disclosed in this specific data set.

What is the role of Matthew Gall in the Tango Therapeutics (TNGX) Form 3?

Matthew Gall is identified as a reporting person and serves as Chief Financial Officer of Tango Therapeutics. The Form 3 records his status as an officer subject to insider reporting rules, even though no specific holdings or trades are detailed here.

Why is a Form 3 filed for Tango Therapeutics CFO Matthew Gall?

Form 3 is filed when someone becomes a reporting insider, such as an officer or director. For Matthew Gall, it formally establishes his reporting status at Tango Therapeutics, even though this excerpt shows no reportable securities positions or transactions yet.